Concepedia

Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions

David S. Hong, Afshin Dowlati, Howard A. Burris, J.J. Lee, Marcia S. Brose, Anna F. Farago, Todd M. Bauer, Matthew H. Taylor, Ashley Shaw, Steven G. Smith,

European Journal of Cancer · 2017 · 10 citations · 0 references

DOI

Concepts